Please ensure Javascript is enabled for purposes of website accessibility

ASH 2017: CAR-T Wallops Blood Cancer

By Todd Campbell - Dec 12, 2017 at 6:14AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ability to beat back blood cancer using gene therapy offers a significant opportunity to improve patient treatment.

The American Society of Hematology (ASH) annual meeting this past weekend was chock-full of excitement, including an unexpected snowstorm in Atlanta and a slew of game-changing non-Hodgkin lymphoma (NHL) and multiple myeloma trial results for chimeric antigen receptor T-cell therapies (CAR-T). These CAR-T trial results suggest we're fast approaching a major shift in how we battle blood cancer, so let's look at the latest data.

A bit of background

Cancer cells often express proteins on their surface that healthy cells usually don't, and CAR-T therapy that targets those proteins is proving to be an effective way to battle back against blood cancer.

A man wearing a suit and boxing gloves.


So far, the FDA has already approved two CAR-T therapies for use in heavily pretreated patients. In August, the FDA approved Novartis' (NVS -0.35%) Kymriah for use in relapsing or refractory acute lymphoblastic leukemia patients. and in October, it OK'd Gilead Sciences' (GILD -1.27%) Yescarta for use in tough-to-treat cases of NHL, including diffuse large B-cell lymphoma (DLBCL).

In both cases, these therapies uncloak cancer cells by using an inactivated virus to insert a gene in a patient's T-cells that allows them to bind to CD19, a protein commonly expressed in B-cell cancers.

Competition's heating up

Novartis filed for FDA approval of Kymriah in DLBCL in October, paving the way for a potential showdown with Yescarta sometime in 2018. At the ASH conference, Novartis unveiled six-month results for Kymriah showing a 37% overall response rate and 30% complete response rate in NHL that matches up similarly to Yescarta.

Gilead Sciences countered with its own long-term follow-up data for Yescarta, showing that 82% of patients responded to it, including 58% of patients who achieved a complete response. At a median of 15.4 months post-infusion, 42% of patients were still achieving a response, including 40% of patients who were in complete remission.

Yescarta's durability is impressive, but Juno Therapeutics' (JUNO) JCAR017 could outmaneuver both Yescarta and Kymirah. JCAR017's results presented at the conference show that it may be as effective as Yescarta and Kymriah, but with far fewer safety risks. A whopping 50% of patients on high-dose JCAR017 were in complete response at the six-month mark, and importantly, far fewer patients suffered from severe-grade cytokine release syndrome and neurotoxicity on JCAR017 than was observed in Yescarta and Kymriah's separate trials.

CAR-T's efficacy isn't limited to NHL, either. At the conference, Celgene (CELG) and bluebird bio (BLUE -14.31%) released updated data from their phase 1 study of bb2121 in heavily pretreated multiple myeloma patients. In that study, 94% of patients responded to bb2121 therapy. The therapy, which targets BCMA, a protein expressed on multiple myeloma cells, delivered a complete response in 56% of patients -- a remarkable proportion because patients participating in the trial had previously failed a median seven prior treatments.

Patients are already enrolling in Celgene and bluebird bio's pivotal study, but it may not have the BCMA market all to itself for long. Juno Therapeutics recently licensed technology from Eli Lilly & Co. and the Fred Hutchinson Cancer Research Center that increases BCMA expression so that its multiple myeloma CAR-T can work better.

Where we go from here

CAR-T therapy is a major advancement in cancer treatment that could save thousands of lives, so investors ought to be paying close attention to the progress these companies are making. Treatment options available to late-stage cancer patients are limited, and real-world use in late-stage patients could clear the way toward CAR-T's use earlier in patient treatment. If so, then these gene therapy companies could end up generating significant sales, because blood cancers such as NHL and multiple myeloma are multibillion-dollar markets.

Todd Campbell owns shares of Celgene and Gilead Sciences. The Motley Fool owns shares of and recommends Bluebird Bio, Celgene, and Gilead Sciences. The Motley Fool recommends Juno Therapeutics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
$5.81 (-14.31%) $0.97
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$65.18 (-1.27%) $0.84
Celgene Corporation Stock Quote
Celgene Corporation
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$316.72 (-0.03%) $0.10
Novartis AG Stock Quote
Novartis AG
$84.92 (-0.35%) $0.30
Juno Therapeutics, Inc. Stock Quote
Juno Therapeutics, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.